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To determine the role of the cysteine proteinase inhibitor cystatin C in the invasive behavior of squamous cell carcinoma of the head
and neck (SCCHN), Cystatin C protein level was measured in 82 pairs of primary tumour tissue and adjacent noncancerous mucosa,
using the enzyme-linked immunosorbent assay. The median level of cystatin C in tumour tissue was 1.18 times lower than that in
corresponding mucosa (P¼0.031). In normal mucosa samples, the cystatin C level was influenced by the site of sampling: it was
lower in nonlaryngeal tissue samples (oral cavity, oro- or hypopharynx) than in laryngeal samples (P¼0.004). The tumour cystatin C
level correlated inversely with pN-stage (P¼0.047), whereas a trend of lower cystatin C levels was observed in the group with
extranodal tumour extension compared to those with no extranodal spread (P¼0.069). In univariate analysis, the patients with low
tumour cystatin C levels exhibited poor disease-free survival (DFS, P¼0.013) and disease-specific survival (DSS, P¼0.013). In
multivariate analysis, the most powerful predictor of survival was pN-stage (DFS: P¼0.040, HR 2.78; DSS: P¼0.011, HR 4.36,),
followed by the cystatin C level (DFS: P¼0.043, HR 0.22; DSS: P¼0.067, HR 0.25). When comparing the prognostic strength of
cystatin C to that of stefin A, another cysteine proteinase inhibitor, which emerged as the most significant prognosticator for survival
in our previous study analysing the same cohort of patients, stefin A proved to be significantly more reliable predictor for both DFS
and DSS than cystatin C. Our results indicate that cystatin C is implicated in the invasive behavior of SCCHN, and that there are
variations in regulation of proteolytic pathways under nonmalignant conditions, inherent to individual subsites inside the upper
aerodigestive tract. The correlation between high cystatin C levels and improved survival concurs with the concept of the protective
role of high levels of cysteine proteinase inhibitors in tissue homogenates that has been previously suggested by the survival results in
breast and lung carcinoma as well as SCCHN.
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Cystatin C is a nonglycosylated 13kDa basic protein, consisting of
120 amino acids. It belongs to the cystatin superfamily of cysteine
proteinase inhibitors. Cystatin C is produced at a constant rate by
all nucleated cells as a preprotein with a hydrophobic leader
sequence of 26 amino acids, indicating an extracellular function of
the inhibitor. Cystatin C protein is a product of the CST3 gene,
which is located on the short arm of chromosome 20. It is freely
filtered in the glomeruli and almost completely reabsorbed and
catabolised in the proximal renal tubular cells (Newman, 2002).
The main physiological role of cystatin C is believed to be the
regulation of cysteine proteinases secreted from the cells or leaked
from the lysosomes during necrotic or apoptotic processes, which
links cystatin C with the aetiology of various diseases, including
cancer (Sloane et al, 1994).
Immunohistochemically, cystatin C protein was stained intra-
cellularly in the cytoplasmic compartment of tumour cells in a
variety of cancer types (Lignelid and Jacobsson, 1992; Lignelid et al,
1997; Yoshimura et al, 2000; Gaumann et al, 2001; Hansen et al,
2001; Yano et al, 2001). The mechanisms controlling the
intracellular inhibition of cysteine proteinases in endosomes and
lysosomes with cystatin C entering the endosomal–lysosomal
pathway by endocytotic uptake may include dimerisation (Ekiel
and Abrahamson, 1996; Merz et al, 1997), proteolytic fragmenta-
tion by cathepsin D (Lenarc ˇic ˇ et al, 1991) or neutrophilic
granulocyte elastase (Abrahamson et al, 1991). Some of these
mechanisms may operate already in the pericellular microenvir-
onment and may restrict the inhibitory function of the secreted
cystatin C against the proteolytic activity of cell surface associated
and/or secreted enzymes (Kr ˇepela et al, 1998).
Immunohistochemical quantification of cystatin C expression
suggested that the concentration of immunoreactive protein in the
cells of some tumour types seems to be below the detection limit.
In the study by Lignelid et al (1997), for example, only a minority
of cystatin C mRNA positive brain and pituitary tumours revealed
cystatin C-immunoreactive tumour cells. In a group of 88
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ymeningiomas, Strojnik et al (2001) detected no immunostaining
for cystatin C in any of the tumours, although Lignelid et al (1997)
reported a 100% positivity for cystatin C transcripts in meningio-
mas. Alternatively, in homogenised preparations used for cystatin
C mRNA determination, cystatin C expressing noncancerous
stromal cells within tumours with otherwise low expression level
of cystatin C in their cancer cells may contribute substantially to
the total cystatin C mRNA level (Lignelid et al, 1997). The same
reproach regarding the origin of cystatin C holds true when
immunobiochemical methods are used for the determination of
cystatin C levels in tissue homogenates. However, a large body of
evidence proved the tissue homogenate levels of proteinases and
inhibitors of various classes to be of significant clinical relevance
(Foekens et al, 1998; Look et al, 2002).
The role of cystatin C in the invasive behavior of squamous cell
carcinoma of the head and neck (SCCHN) has not been
investigated so far. The aim of the present study was to determine
the levels of cystatin C in the tissue homogenates of SCCHN and its
surrounding noncancerous mucosa. As SCCHN is an extremely
heterogenous disease, it is little surprise that no factor within the
wide spectrum of biochemical and histological factors has yet been
identified as reliably predicting the natural course of the disease or
its response to therapy (Lal, 1994; Quon et al, 2001). Thus, the
results of the study have been related to established clinical and
histopathological features, considering especially the correlation of
individual tumour levels of cystatin C with patients’ survival.
MATERIALS AND METHODS
Patients
In total, 82 previously untreated patients with primary operable
SSCHN entered the study. Of these patients, five were females and
77 males, ranging in age from 37 to 72 years (median age: 59
years). This cohort of patients was the same as in our previous
report, examining the prognostic significance of cysteine protei-
nases cathepsins B and L and their intracellular inhibitors A and B
(Strojan et al, 2000).
In all patients, therapeutic surgery was performed. It comprised
the resection of the primary tumour, related to the lesion
extension, together with a surrounding margin of normal tissue,
and removal of the related regional lymph nodes from the neck.
Postoperative radiotherapy was applied in 74 patients, because of
an advanced stage of disease, extranodal tumour spread, residual
growth after surgery, or the presence of neoplastic emboli in the
lymphatic vessels. The patients were irradiated on a Cobalt-60 unit
or a 5-MV linear accelerator, with a daily dose of 1.8–2.0Gy, 5
days per week. Radiotherapy doses were adapted to the disease
extent and ranged from 50 to 66Gy (median dose: 56Gy), It was
delivered through two opposing lateral fields to the primary
tumour and regional lymph nodes, with spinal cord shielded after
a dose of 40–44Gy. One anterior field was added to cover the
lower neck lymphatics.
Tumours were staged according to UICC pTNM classification
after histopathological examination of surgical specimens (Sobin
and Wittekind, 1997). The histopathological grade was defined
according to WHO criteria (Azzopardi et al, 1981). Clinical and
histopathological characteristics of tumours are shown in Table 1.
Sample collection
From operative specimen, two tissue samples of 200–500mg,
representing matched pairs, were obtained from the tumour and
adjacent normal mucosa. Immediately after removal, they were
immersed in liquid nitrogen until homogenate preparation. Fat
and necrotic parts were carefully removed. Pulverisation was
performed on the frozen tissue with a Mikro-Dismembranator
(Braun, Melsungen, Germany) for 60s at maximum power, and the
resulting tissue powder was suspended in an extraction buffer
consisting of 5mM Na2HPO4,1 m M monothioglycerol, and 10%
vv
 1 glycerol (pH 7.4). The suspension was centrifuged for 45min
at 100000 g to obtain a supernatant, that is homogenate, which
was divided into aliquots and stored at  701C until use.
Determination of cystatin C
Cystatin C concentrations were determined by enzyme-linked
immunosorbent assay (KRKA d.d., Novo mesto, Slovenia).
Recombinant human cystatin C was expressed in Escherichia coli
as described (Cimerman et al, 1999) and used for the immunisa-
tion of animals and the preparation of calibration curves. Rabbit
polyclonal antibody (IgG), purified from antisera by affinity
chromatography on immobilised cystatin C, was used as capture
antibody and murine 1A2 monoclonal antibody, conjugated to
horseradish peroxidase, was used for detection (Kos et al, 2000a).
Antibodies were specific for recombinant and native human
cystatin C, and recognised free inhibitor and cathepsin-inhibitor
complexes. Crossreactivity between closely related inhibitors of
cysteine proteinases (human stefins A and B) was excluded by
immunoblot and ELISA.
Linearity and recovery of ELISA was tested as described (Kos
et al, 2000a). A microplate reader was used to measure the
absorbance (SLT Rainbow, Salzburg, Austria) in ELISA. The
concentration of cystatin C was expressed in ngmg
 1 of total
protein (ngmgp
 1).
Tumour samples at 1:20 dilution and normal tissue samples at
1:10 dilution were added to the wells of a microtitre plate
precoated with rabbit anticystatin C IgG. After 2h of incubation at
Table 1 Tumour parameters of 82 patients with operable squamous cell
carcinoma of the head and neck
Primary tumour site
Oral cavity 14
Oropharynx 18
Hypopharynx 10
Larynx 40
UICC pTNM-classification
N0 N1 N2 N3 Total
T1 31 2 0 6
T2 11 3 13 1 28
T3 14 1 9 0 24
T4 9 2 13 0 24
Total 37 7 37 1 82
Overall stage
StageI 3
StageII 12
StageIII 19
StageIV 48
Histopathological grading
Well differentiated, G1 3
Moderately differentiated, G2 68
Poorly differentiated, G3 11
Extranodal extention
a
Negative 15
Positive 30
Tumour emboli in lymph node vessels
a
Negative 37
Positive 8
apN+ patients only, n¼45.
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y371C, the wells were washed and murine monoclonal 1A2
anticystatin C antibody, which was purified by the affinity
chromatography on Protein A-Sepharose and conjugated subse-
quently with horseradish peroxidase, was added. After a further 2h
of incubation at 371C, 3,3,4,4-tetramethyl benzidine (Sigma, St
Louis, MO, USA) in the presence of hydrogen peroxide was added.
The amount of degraded substrate, as a measure of bound
immunocomplexed cystatin C, was visualised by absorbance at
450nm. The cystatin C concentration was calculated from the
calibration curve.
Determination of proteins
Protein concentrations were determined according to the Bradford
method (Bradford, 1976). Bovine serum albumin was used as a
standard.
Statistical analysis
The results were analysed using a PC and the SPSS statistical
package (Release 10.0, SPSS Inc., Chicago, IL, USA). The difference
between the median concentrations of cystatin C in matched pairs
of tumour and normal tissue samples was determined by the
Wilcoxon signed-rank test. The Mann–Whitney U test was used to
test the relationship between the median values of the tumour
tissue cystatin C concentrations in different groups of patients. The
difference in distribution of pTNM-stages between the patients
with laryngeal tumours and those with nonlaryngeal tumours was
tested with a w
2 test.
Univariate analysis of the patients’ survival was carried out
using the Kaplan–Meier product-limit method (Kaplan and Meier,
1958) and log-rank comparison to evaluate the difference between
the survival curves (Peto et al, 1977). The primary end points of
survival analysis were disease-free survival (DFS) and disease-
specific survival (DSS). In the former case, the local and/or
regional recurrence and/or systemic dissemination was considered
as an event, whereas the latter was calculated by censoring deaths
from disease-unrelated causes. The survival times were calculated
from the date of surgery. Cystatin C concentrations were
dichotomised into low and high groups after optimisation of the
cutoff level, using the Critlevel method as described by Abel et al
(1984). Multivariate analysis was performed according to Cox’s
proportional hazard model (Cox, 1972). All of the tests were two-
sided and the results were considered significant at a probability
level below 5%.
The study protocol was approved by the Medical Ethics
Committee at the Ministry of Health of the Republic of Slovenia.
All of the included patients gave their informed consent to
voluntary participation in the study.
RESULTS
Distribution of cystatin C concentrations and relation to
clinical and histopathological parameters
The concentrations of cystatin C in 82 tissue homogenates of
tumour and corresponding nontumorous mucosa are summarised
in Table 2. The cystatin C concentration was significantly
(Po0.0001) decreased by a factor of 2.44 in 37 (45%) tumours
and was elevated 2.04-fold in 45 cases (55%), still resulting in a
1.18-fold significant (P¼0.041) decrease in inhibitor concentra-
tion in the total population of tumour samples compared to their
control counterparts. Furthermore, the cystatin C levels in control
samples in the group where an increase was observed was
significantly lower than in the control group with decreased
inhibitor (Po0.0001).
In normal mucosa samples, the cystatin C level was influenced
by the site of sampling, being lower in nonlaryngeal tissue samples
(i.e., from the oral cavity, oropharynx or hypopharynx) than in the
laryngeal ones (11.5 vs 24.0 ngmgp
 1 P¼0.004). With regard to
the cystatin C levels in tumour tissue or the distribution of
downregulated and upregulated cases, no difference was found
between these two major groups of tumours.
The data were further analysed with respect to the established
clinical and histopathological parameters. No correlation was
found between tumour cystatin C level on the one hand and, on the
other hand, patients’ age and sex, histopathological tumour grade,
pT-stage and the overall UICC pTNM-stage of the disease, and the
presence of tumour emboli in the lymphatic vessels as determined
in a histological examination of a resected tissue specimen from
the neck. The tumour cystatin C level correlated inversely with pN-
stage (pN0 vs pNþ: 18.4 vs 14.2ngmgp
 1, P¼0.047), whereas a
trend of lower cystatin C levels was observed in the group with
extranodal tumour extention compared to that with no extranodal
spread (14.0 vs 17.4ngmgp
 1, P¼0.069).
The analysis was repeated separately on laryngeal and
nonlaryngeal tissue samples. In matched pairs of normal mucosa
and tumour tissue, statistically significant (P¼0.029) decrease in
tumour cystatin C concentration was found in the group of
laryngeal tumours: compared to the normal tissue counterparts,
Table 2 Concentrations of cystatin C in tissue homogenates of tumours and adjacent normal mucosa
Cystatin C
a
Mucosa Tumour
Patients Median Range Median Range P-value
b
All (n¼82) 16.7 2.9–81.2 14.2 7.5–49.1 0.041
Group 1
c (n¼37) 33.7
d 8.7–81.2 13.8
e 7.6–27.9 o0.0001
Group 2
c (n¼45) 9.1
d 2.9–26.8 18.5
e 7.5–49.1 o0.0001
With laryngeal tumours (n¼40) 24.0 5.4–79.9 16.9 7.5–49.1 0.029
Group 1
c (n¼22) 37.7 11.0–79.9 12.9 7.6–27.9 0.0001
Group 2
c (n¼18) 9.7 5.4–26.8 26.1 7.5–49.1 0.001
With nonlaryngeal tumours (n¼42) 11.5 2.9–81.2 14.8 8.0–40.1 NS
Group 1
c (n¼15) 23.8 8.7–81.2 14.5 8.0–21.9 0.0001
Group 2
c (n¼27) 8.5 2.9–25.1 14.9 9.1–40.1 o0.0001
aConcentration, in ngmg
 1 total protein.
bMucosa vs tumour.
cPatients with decreased (Group 1) and increased (Group 2) concentration of cystatin C in tumour compared to
mucosa.
dMucosa: Group 1 vs Group 2, Po0.0001.
eTumour: Group 1 vs Group 2, P¼0.009. NS¼not significant.
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The inhibitor decreased significantly (P¼0.0001), 2.92-fold in 55%
of tumours, and was elevated 2.69-fold in 45% of cases (Table 2).
No correlation with established clinical or histopathological
prognostic factors was observed in this group of tumours. Among
nonlaryngeal tumour samples, no difference was found in matched
pairs of normal mucosa and its tumour counterparts, and
marginally significant trend of higher cystatin C concentrations
was observed in early disease compared to advanced tumours
(UICC pTNM stages I–II vs III–IV: 18.1 vs 13.8ngmgp
 1,
P¼0.052).
Survival analysis
As of 31 December 2002 (close-out date), disease relapsed in 22
patients and 50 patients died: 20 due to disease recurrence and/or
dissemination and 30 due to causes other than the treated
malignant disease. In total, 32 patients were alive with no signs
of the disease. The median follow-up period of all eligible patients
was 4.3 years (range: 0.1–10.0 years), and was 6.5 years (5.2–10.0
years) for those alive at the last follow-up examination.
Actuarial DFS rates at 5 and 10 years were 70%, and the DSS
rates were 73%. On univariate analysis, the patients with tumours
involving neck nodes (pNþ) and more advanced disease (overall
UICC pTNM-stage), and those in whom extranodal tumour spread
or tumour emboli were determined in the lymphatic vessels,
exhibited a significantly higher risk of relapse or disease-specific
death (Table 3). When using a median cystatin C concentration to
classify tumours as cystatin C-low and cystatin C-high, no
difference in survival was observed between the groups. However,
after optimisation, the cystatin C cutoff value was found to be the
68th percentile in the group and was identical for DFS and DSS,
giving in both cases a P-value of 0.013. As compared to the group
with low tumour levels of cystatin C, patients with higher tumour
contents of the inhibitor experienced significantly longer survival
(Table 3, Figure 1).
In multivariate analysis, the prognostic value of cystatin C was
compared to the values of pN-stage, UICC pTNM-stage, extranodal
tumour spread and the presence of tumour emboli in the
lymphatic vessels. Variables were eliminated singly in a backward
manner with exclusion if P40.050. For DFS, pN-stage (P¼0.040,
HR¼2.78, 95% CI 1.25–6.38) and cystatin C (P¼0.043,
HR¼0.22, 95% CI 0.08–0.66) were retained in the final model,
and for DSS, pN-stage only (P¼0.011, HR¼4.36, 95% CI 1.6–
9.55). In the latter case, cystatin C turned out to be of marginal
significance (P¼0.067, HR¼0.25, 95% CI 0.07–0.90). As in the
same cohort of patients stefin A has been identified previously as
the most powerful prognosticator for both DFS and DSS, the
standardised concentrations of the latter, calculated as described in
our previous report, was also introduced in Cox model (Strojan
et al, 2000). Using the Critlevel method, the concentrations of
stefin A were dichotomised into low and high groups at cutoff
level, which turned to be the 25th percentile in the group.
Comparing both inhibitors, stefin A proved to be stronger and the
only significant predictor for survival (DFS: P¼0.003, HR¼0.27,
95% CI 0.11–0.63; DSS: P¼0.004, HR¼0.26, 95% CI 0.11–0.65).
In addition, to determine whether the combination of the two
variables would increase the prognostic stratification of the
patients, they were grouped as follows: high cystatin C and high
stefin A – low-risk group (23 patients); high cystatin C and low
stefin A, or low cystatin C and high stefin A – medium-risk group
(41 patients); and low cystatin C and low stefin A – high-risk group
(18 patients). We found statistically highly significant difference
between the three prognostic groups for both DFS and DSS
(Po0.0001, Figure 2).
DISCUSSION
An alteration of the balance between cysteine cathepsins and their
endogenous inhibitors has been demonstrated to correlate with
neoplastic transformation, tumour invasion and metastasis (Sloane
et al, 1994). The tissue and serum levels of these enzymes and
inhibitors in a variety of human tumours have been shown to
predict the disease-free and overall survival period, and may
therefore serve as prognostic factors for cancer patients. However,
the investigations mainly focused on cathepsins B and L, stefins,
and the most frequent cancer types, that is, carcinoma of the
breast, lung and colorectum (Kos and Lah, 1998). Much less is
known about cystatin C, even though it has been used in clinical
research studies for more than 20 years, preferentially as a
candidate marker for detection of impaired glomerular filtration
Table 3 Univariate analysis of survival
Disease-free survival Disease-specific survival
Variable No. of patients % at 5 years 95% CI P-value % at 5 years 95% CI P-value
pN-stage
pN0 37 89 76–100 0.009 90 78–100 0.008
pN+ 45 61 43–79 59 40–78
UICC pTNM-stage
StageI–III 34 87 73–100 0.015 93 82–100 0.001
StageIV 48 57 40–74 58 41–75
Extranodal spread
Negative
a 52 82 69–95 0.001 89 78–100 o0.0001
Positive 30 48 28–68 45 24–66
Tumour emboli
Negative
a 74 71 59–83 0.027 75 63–87 0.021
Positive 8 27 5–49 25 2–48
Cystatin C
Low 56 61 45–77 0.013 64 48–80 0.013
High 26 90 76–100 91 78–100
aPatients with no evidence of regional metastases (i.e. pN0) are also included. CI¼confidence interval.
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yrate (Newman, 2002). Based on high extracellular concentrations
and inhibitory kinetics of cystatin C, it has also been shown as the
most powerful extracellular inhibitor for several cysteine protei-
nases. Therefore, the majority of clinical work has been related to
cystatin C activity and protein level determination in fluids
surrounding tumours, mainly in the blood and urine (Kos et al,
2000b).
In the present study, a significantly lower concentration of
cystatin C was found in the total population of tumour
homogenates compared to normal mucosa, although two groups
of patients with downregulated and upregulated cystatin C
concentration were distinguished. At this point, the crucial
question is whether the observed relations in cystatin C levels
influenced the total intracellular proteolytic potential in the two
groups. It has been shown that alterations in total inhibitory
activity of cysteine proteinase inhibitors or in protein level in case
of stefin A were present in malignant tissue and normal
parenchyma of the breast (Lah et al, 1992, 1997) and lung (Knoch
et al, 1994). In the study by Lah et al (1992), lowered cysteine
proteinase inhibitor activity in breast carcinoma tissue (i.e., in the
low-activity group) was associated with significantly higher
increases of cathepsin B and cathepsin L activities than those
measured in the high-activity group, indicating higher proteolytic
potential in the former group. In the low-activity group, more
patients developed poorly differentiated and hormone receptor-
negative tumours. After a 2-year follow-up, however, recurrences
were reported in the same percentage in both groups of patients.
Neither in lung cancer (Knoch et al, 1994) nor in the present study
(data not shown) was a significant difference between the two
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Figure 1 Actuarial DFS and DSS as a function of cystatin C
concentration. The cutoff value was determined as described in the text.
Numbers in parentheses indicate number of recurrences (or deaths)/total
in each group.
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Figure 2 Prognostic significance of the combination of cystatin C and
stefin A concentrations: DFS and DSS. The cutoff value was determined as
described in the text. Numbers in parentheses indicate number of
recurrences (or deaths)/total in each group (LR¼low-risk group;
MD¼medium-risk group; HR¼high-risk group).
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ygroups with respect to survival probability observed. In our study
it is noteworthy that cystatin C level in control samples of the
group of cystatin C positive tumours was significantly lower than
in the control group with decreased inhibitor. Lah et al (1997), who
reported on similar change for the inhibitory activity of cystatins
and stefin A protein level in normal breast tissue, hypothesised
that the relative increase in cystatin activity/levels was due to both
an increase of cystatins in tumours and their decrease in control
tissues. The latter suggested a downregulation of cystatin C in
stromal tissue adjacent to the tumour, possibly induced by tumour
cells.
Specifically for cystatin C, alterations were described at various
levels of protein synthesis. Yano et al (2001) reported on the
tendency of lower cystatin C mRNA expression in breast cancer
tissue than in noncancerous tissue, and significantly lower
expression of cystatin C relative to cathepsin B in cancerous
tissue. Downregulation of cystatin C gene was found in large
granular lymphocyte leukaemia (Kothapalli et al, 2003). On the
contrary, in squamous-cell lung cancer, no alteration in cystatin C
protein level was described in matched pairs of normal and
tumour tissue homogenates (Ebert et al, 1997; Kepela et al, 1998)
and, in colorectal cancer, a similar cystatin C mRNA level was
found in cancerous and noncancerous tissue, which tended to
show an inverse correlation with the cathepsin B levels (Hirai et al,
1999). The possibility of a similar number of pairs with equally
increased and decreased cystatin C mRNA or protein level in these
studies, resulting in the same average, could not be excluded.
The correlation between cysteine proteinases, their inhibitors
and tumour malignancy is likely to be a qualitative rather than a
quantitative one. Thus, the proteolytic activity in tumours might
be affected not only by the alterations in synthesis but also in
processing, subcellular localisation and secretion of the enzymes
and their inhibitors. As a result, in breast cancer, the cathepsin B
and L activities were found to be much more increased than the
respective protein levels, suggesting that the increase in activity
was not entirely due to the induction of the respective proteins
(Lah et al, 1997). The changes in molecular structure of inhibitors
may decrease the binding affinity for the target enzymes, as
described by Lah et al (1989) for stefin A in human sarcoma. In
lung tumour tissue, cathepsin B was found to be more resistant to
inactivation by E-64 than cathepsin B from control lung tissue
(Kr ˇepela et al, 1995). Furthermore, it has been shown that the
serum level of cathepsin B/cystatin C complexes was significantly
decreased in patients with malignant lung tumours than in healthy
controls (Zore et al, 2001). Additionally, higher total concentra-
tions of cystatin C found in sera of patients with lung, colorectal
and melanoma cancer (Kos and Lah, 1998) suggested enhanced
secretion of cystatin C from tumour cells, increasing at the same
time the intracellular proteolytic potential of cysteine proteases.
Association of enhanced secretion of cystatin C with invasive
potential has been found in various cell lines (Kos et al,
manuscript in preparation).
A large body of literature has been accumulated to suggest that
cystatin C participated not only in the transformation of cells to a
malignant state but also in tumour growth, invasion and
metastasis. In cystatin C transfected B16 melanoma cells, the
overexpression of inhibitor resulted in the inhibition of melanoma
cell mobility and of the ability to penetrate artificial matrices by
about 50% (Sexton and Cox, 1997), as well as in the suppression of
metastasis by at least 90%, compared to controls (Cox et al, 1999).
Similarly, the overproduction of active recombinant cystatin C
resulted in a pronounced reduction in Matrigel invasion of murine
squamous carcinoma cells (Coulibaly et al, 1999). In human
glioblastoma cells, inverse correlation between cystatin C and
tumour grade was observed (Konduri et al, 2002). The sence-
cystatin C transfected cells were also markedly less invasive than
the control cells and, in nude mice, did not form tumours upon
intracerebral injection. Furthermore, it was suggested that cystatin
C and cathepsin B interaction may participate in the modulation of
the invasive phenotype of human colonic tumours (Corticchiato
et al, 1992). In the mouse lymphosarcoma model, the cystatin C
concentrations in the plasma and other tissues reliably reflected
the changes in tumour volume following cytotoxic therapy
(Poteryaeva et al, 2001). In our study, we observed inverse
correlation between the tumour cystatin C level and more
aggressive forms of the disease (i.e., involved neck nodes,
extranodal tumour spread), which also links the alterations in
cystatin C expression with the invasive behavior of SCCHN. The
fact that the intracellular inhibitors of cysteine proteases regulate
the degradation of extracellular matrix, a crucial step in invasion
process, is apparently contradictive. However, it has been shown
that the extracellular matrix can be internalised and partially
degraded in the tumour cells (Szpaderska and Frankfater, 2001).
The role of intracellular fraction of cystatin C in regulating this
process has to be distinct from those of stefins A and B due to
different subcellular localisation and inhibitory profile against
cysteine proteases.
There is good evidence that all nucleated cells constitutively
express cystatin C. However, variability in the degree of cystatin C
gene expression in different tissues, which could be further
influenced by several factors, provides evidence for the differential
regulation of cystatin C expression in different tissues (Newman,
2002). In the present study, the results of cystatin C measurements
in normal mucosa were influenced by the site of sampling. Cystatin
C levels were significantly lower in the homogenates prepared from
nonlaryngeal tissue samples than in the homogenates from the
laryngeal tissue. Thus, considering the inherent variations in the
regulation of proteolytic pathways between individual subsites
inside the upper aerodigestive tract, at least two groups of tissues
should be distinguished in further studies.
Concerning the results on survival in our study, two points
should be stressed. To our knowledge, this is the only study
evaluating the prognostic significance of cystatin C in SCCHN and
no data are available at the moment for comparison. Second, the
study population was quite homogenous in respect to the selection
of the patients (all had operable tumours) and therapy. In
multivariate analysis, only the prognostic power of the pN-stage
of disease outweighs that of cystatin C. However, when comparing
the prognostic strength of cystatin C with that of stefin A, which
emerged as the most significant prognostic factor in our previous
study analysing the same population of patient, cystatin C lost its
significant prognostic power for both DFS and DSS. In addition,
the combination of the two inhibitors, cystatin C and stefin A,
could further stratify the risk of adverse event as was the case with
stefin B and cathepsin B in colorectal cancer (Kos et al, 2000a).
The correlation between high levels of tumour cystatin C and the
longer survival of our patients concurs with the concept of
protective role of high levels of cysteine proteinase inhibitors in
tissue homogenates. This concept has been proposed following the
survival results in the carcinoma of the breast (Lah et al, 1997),
lung (Knoch et al, 1994; Ebert et al, 1997), and head and neck
(Strojan et al, 2000). Two studies apparently contradict this
assumption, specifically regarding cystatin C. In colorectal cancer
(Kos et al, 2000a) and lung cancer (Kos et al, unpublished results),
the patients with high serum levels of cystatin C exhibited a
significantly higher risk of death than those with lower levels of
inhibitor, whereas a decreased metastatic spread was found in
cystatin C deficient mice compared to wild-type mice (Huh et al,
1999). As mentioned above, alterations in secretion may result in
higher extracellular and lower intracellular levels of cystatin C and,
therefore, the reverse correlation of serum cystatin C with patients’
survival is to be expected. On the other hand, one has to be aware
that cysteine proteases and consequently their inhibitors are also
involved in biological processes other than tissue remodelling
during the progression of primary tumours, such as the regulation
of inflammatory and immune responses (Chapman et al, 1997) or
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systemic level may lead to a lower metastatic spread compared to
wild-type animals.
In conclusion, our data indicate that cystatin C is implicated in
the invasive behavior of SCCHN. The variations in regulation of
proteolytic pathways seem to be the inherent characteristic of
individual subsites inside the upper aerodigestive tract, which
should be considered in further studies. Moreover, the protective
role of high levels of cystatin C in tissue homogenates was
suggested, as it had been proposed for some other cysteine
proteinase inhibitors by the survival results in breast and lung
cancer as well as in SCCHN. When comparing the prognostic
strength of cystatin C to that of stefin A, the latter emerged as
significantly more reliable predictor for survival.
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